rivaroxaban NDC 55488-0541

NDC codes

FDA NDC Directory

Product NDC (as listed)55488-0541Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55488-0541Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55488-0541-1	55488054101	30 TABLET, FILM COATED in 1 BOTTLE (55488-0541-1)Marketed from Feb 1, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): rivaroxaban
Generic name (nonproprietary): rivaroxaban
Active ingredients: Rivaroxaban — 15 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Changzhou Pharmaceutical Factory
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216995
Marketing start: Feb 1, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Factor Xa Inhibitors (Mechanism)
Identifiers: Product ID 55488-0541_8b1205ed-1f1c-4e13-8076-aefada9213adSPL ID 8b1205ed-1f1c-4e13-8076-aefada9213adSPL set ID 9178947d-9d58-4c1a-b158-6030e17556afRxCUI 1114198, 1232082, 1232086UNII 9NDF7JZ4M3UPC 0355488054114, 0355488054015, 0355488054213
Pharmacologic class: Factor Xa Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455488054101 followed by a unit qualifier and the quantity

Package 55488-0541-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 11, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Rivaroxaban is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disea…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216995

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216995
Product	Strength	Form · route	Labeler	Product NDC
rivaroxaban	Rivaroxaban 10 mg/1	Tablet, Film coatedOral	Changzhou Pharmaceutical Factory	55488-0540
rivaroxaban	Rivaroxaban 20 mg/1	Tablet, Film coatedOral	Changzhou Pharmaceutical Factory	55488-0542